N2-[cis-4-[[2-[4-Bromo-2-(trifluoromethoxy)phenyl]ethyl]amino]cyclohexyl]-N4,N4-dimethyl-2,4-quinazolinediaminedihydrochloride manufacturers
- ATC0065 HCl
-
- $1980.00
-
2026-07-15
- CAS:510732-84-0
- Purity:
- Supply Ability: 10g
|
| | N2-[cis-4-[[2-[4-Bromo-2-(trifluoromethoxy)phenyl]ethyl]amino]cyclohexyl]-N4,N4-dimethyl-2,4-quinazolinediaminedihydrochloride Basic information |
| | N2-[cis-4-[[2-[4-Bromo-2-(trifluoromethoxy)phenyl]ethyl]amino]cyclohexyl]-N4,N4-dimethyl-2,4-quinazolinediaminedihydrochloride Chemical Properties |
| storage temp. | Desiccate at RT | | solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | | form | Powder |
| | N2-[cis-4-[[2-[4-Bromo-2-(trifluoromethoxy)phenyl]ethyl]amino]cyclohexyl]-N4,N4-dimethyl-2,4-quinazolinediaminedihydrochloride Usage And Synthesis |
| Uses | ATC 0065 has a high affinity for human melanin-concentrating hormone R1 (MCHR1) with an IC50 value of 15.7±1.95. ATC 0065 is a potent and orally active MCHR1 antagonist with anxiolytic and antidepressant activity in rodents. | | in vivo | ATC0065 (3-30 mg/kg; oral administration; 3 h prior to the test) shows antidepressant-like effects in rats[1]. | Animal Model: | Male SpragueDawley rats (190-250 g) forced swimming[1] | | Dosage: | 3 mg/kg, 10 mg/kg, 30 mg/kg | | Administration: | Oral administration; 3 h prior to the test | | Result: | Significantly reduced immobility time in the forced swimming. |
|
| | N2-[cis-4-[[2-[4-Bromo-2-(trifluoromethoxy)phenyl]ethyl]amino]cyclohexyl]-N4,N4-dimethyl-2,4-quinazolinediaminedihydrochloride Preparation Products And Raw materials |
|